New hope for Hard-to-Treat prostate cancer: targeted drug combo shows promise
NCT ID NCT03012321
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 32 times
Summary
This study tests three treatment options in men with advanced prostate cancer that has stopped responding to hormone therapy and has specific DNA repair defects. Participants receive either abiraterone (a hormone blocker), olaparib (a targeted drug), or both together. The goal is to see which approach delays cancer growth best. About 70 men will take part, and the study is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Huntsman Cancer Institute - University of Utah
Salt Lake City, Utah, 84112, United States
-
Indiana University/ Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Kellogg Cancer Center - NorthShore University
Evanston, Illinois, 60201, United States
-
Northwestern Medicine
Chicago, Illinois, 60611, United States
-
Rush University Cancer Center
Chicago, Illinois, 60612, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
-
University of California Los Angeles
Los Angeles, California, 90073, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109-5946, United States
-
University of Michigan Rogel Cancer Center
Detroit, Michigan, 48201, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University of Virginia
Charlottesville, Virginia, 22903, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.